Dr Seema Ahsan Khan speaks to ecancer about her ASCO 2020 virtual presentation, investigating systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer.
Dr Khan explains that the treatment of the intact primary tumour in the breast may be effective and improve survival following systemic therapy.
She outlines the methods for this randomised phase III trial, and states the research group did not find any benefit related to the use of surgery and radiation for treatment of the primary tumour - as the overall survival in these two arms were equal.
Quality of life (QoL) was also assessed as a secondary endpoint, and the group did not find any difference between these two arms either - suggesting that QoL was impaired to an equal degree.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.